Frontier Pharma: Alzheimer’s Disease - Identifying and Commercializing First-in-Class Innovation

1
Frontier Pharma Alzheimers Disease -
Identifying and Commercializing First-in-Class
Innovation
Single User License - 6995 Site User
License - 13990 Corporate User License -
20985 Publication Date - Nov 2014 Pages -
101 To know more details, email to
debora_at_reportstack.com
2
Summary

• The active Alzheimers Disease (AD) pipeline is
  populated with 583 products, with a highly
  diverse range of molecular targets. GBI Research
  analysis revealed a high degree of innovation in
  this indication, with 46 of the pipeline being
  first-in-class products, acting on over 40
  first-in-class molecular targets. In addition,
  the pipeline is characterized by the strong
  presence of therapies that target multiple
  components implicated in the amyloid cascade,
  several molecular targets of which are known to
  trigger familial AD. Given that the currently
  approved therapies for AD are limited to
  acetylcholinesterase inhibitors and glutamate
  receptor antagonists, the pipeline offers a broad
  range of treatment options that may possess
  disease-modifying properties.

3
Scope

• A brief introduction to AD, including symptoms,
  pathophysiology, and overview of pharmacotherapy
  and treatment algorithms
• The changing molecular target landscape between
  market and pipeline and particular focal points
  of innovation in the pipeline
• A comprehensive review of the pipeline for
  first-in-class therapies, analyzed on the basis
  of stage of development, molecule type and
  molecular target
• Identification and assessment of first-in-class
  molecular targets with a particular focus on
  early-stage programs for which clinical utility
  has yet to be evaluated, as well as literature
  reviews of novel molecular targets

4
Key Benefits

• Understand the focal shifts in molecular targets
  in the AD pipeline
• Understand the distribution of pipeline programs
  by phase of development, molecule type and
  molecular target
• Access a scientific and clinical analysis of
  first-in-class developmental programs for AD,
  benchmarked against non-first-in-class targets
• Access a list of the first-in-class therapies
  potentially open to deal-making opportunities

5
If you are interested...
Contact Debora White Email
debora_at_reportstack.com Ph1-888-789-6604 http/
/www.reportstack.com